Overview

PrEPsmart 2-1-1 Pilot

Status:
RECRUITING
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
This is a pilot study to assess the feasibility, acceptability, and preliminary effectiveness of pre-exposure prophylaxis (PrEP)smart among cisgender sexual minority males (SMM) taking on-demand PrEP over a 6-month period. Upon project completion, the investigators will have developed a highly innovative tool to support men who have sex with men (MSM) using on-demand PrEP ready for testing in a larger efficacy trial
Phase:
PHASE2
Details
Lead Sponsor:
Public Health Foundation Enterprises, Inc.
Collaborator:
Gilead Sciences
Treatments:
Emtricitabine
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Tenofovir